» Articles » PMID: 31745330

Antibiotic Development - Economic, Regulatory and Societal Challenges

Overview
Date 2019 Nov 21
PMID 31745330
Citations 132
Authors
Affiliations
Soon will be listed here.
Citing Articles

Innovative perspectives on the discovery of small molecule antibiotics.

Cardona S, Rahman A, Novomisky Nechcoff J NPJ Antimicrob Resist. 2025; 3(1):19.

PMID: 40082593 PMC: 11906701. DOI: 10.1038/s44259-025-00089-0.


The social burden of antimicrobial resistance: what is it, how can we measure it, and why does it matter?.

Keenan K, Silva Correa J, Sringernyuang L, Nayiga S, Chandler C JAC Antimicrob Resist. 2025; 7(2):dlae208.

PMID: 40065828 PMC: 11891513. DOI: 10.1093/jacamr/dlae208.


Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.

Abdel-Razek M, Nazeih S, Yousef N, Askoura M AMB Express. 2025; 15(1):37.

PMID: 40044971 PMC: 11882492. DOI: 10.1186/s13568-025-01846-0.


Development of Novel Tc-Labeled Hydrazinoicotinamide-Modified Ubiquicidin 29-41 Complexes with Improved Target-to-Nontarget Ratios for Bacterial Infection Imaging.

Jiang Y, Wang Q, Yin G, Feng J, Ruan Q, Han P ACS Pharmacol Transl Sci. 2025; 8(2):470-483.

PMID: 39974636 PMC: 11833726. DOI: 10.1021/acsptsci.4c00599.


An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections.

Muir B, Payne J, Martin J, O Shea R, Rajesh S, Blackman L NPJ Antimicrob Resist. 2025; 3(1):9.

PMID: 39966608 PMC: 11836273. DOI: 10.1038/s44259-024-00070-3.


References
1.
Mullard A . Smallest biopharma firms are pushing more of the pipeline. Nat Rev Drug Discov. 2019; 18(6):411. DOI: 10.1038/d41573-019-00084-x. View